Flook, M.
Jackson, C.
Vasileiou, E.
Simpson, C. R.
Muckian, M. D.
Agrawal, U.
McCowan, C.
Jia, Y.
Murray, J. L. K.
Ritchie, L. D.
Robertson, C.
Stock, S. J.
Wang, X.
Woolhouse, M. E. J.
Sheikh, A.
Stagg, H. R. http://orcid.org/0000-0003-4022-3447
Funding for this research was provided by:
Medical Research Council (MR/R008345/1, MC_UU_12023/26, MR/R008345/1, MR/R008345/1)
Wellcome Trust (WT 209560/Z/17/Z)
National Institute for Health Research (11/46/23)
New Zealand Health Research Council (20/1018)
Ministry for Business, Innovation and Employment, New Zealand
Article History
Received: 17 June 2020
Accepted: 16 March 2021
First Online: 12 April 2021
Declarations
:
: This is a systematic review and therefore presents secondary data. No ethical approvals were required.
: Not applicable.
: CR is a member of the Scottish Government’s Chief Medical Officer’s COVID-19 Advisory Group, a member of the UK SPI-M committee and the Commission Human Medicines COVID-19 Vaccine Safety Benefits and Risks Working Group. JLKM is Incident Director for COVID-19 at Public Health Scotland and reports no conflicts of interest. LDR serves on a number of Scottish Government Advisory Groups, including COVID-19. MEJW is a member of the SPI-M advisory committee for the UK Government and the Covid-19 Advisory Group for the Scottish Government. AS is a member of the Scottish Government’s Chief Medical Officer’s COVID-19 Advisory Group and the New and Emerging Respiratory Virus Threats (NERVTAG) Risk Stratification Subgroup. HRS is an advisor to the Scottish Parliament’s COVID committee. The views represented in this article do not represent the views of the UK or Scottish Government. All other authors declare that they have no competing interests.